Read by QxMD icon Read

Larynx chemotherapy

William A Stokes, Bernard L Jones, Shilpa Bhatia, Ayman J Oweida, Daniel W Bowles, David Raben, Julie A Goddard, Jessica D McDermott, Sana D Karam
BACKGROUND: Although laryngectomy is the treatment of choice for patients with T4 larynx cancer, many patients are unable or unwilling to undergo laryngectomy and instead pursue larynx-preservation strategies combining radiotherapy (RT) and chemotherapy. Herein, the authors analyzed the National Cancer Data Base to evaluate overall survival (OS) between patients treated with surgical and organ-preserving modalities. METHODS: The National Cancer Data Base was queried for patients diagnosed from 2004 through 2012 with T4M0 laryngeal cancer who underwent either laryngectomy (surgery) with adjuvant RT (SRT), chemotherapy starting concurrently within 7 days of RT (CCRT), or multiagent induction chemotherapy starting 43 to 98 days before RT (ICRT)...
October 11, 2016: Cancer
A S R Mohamed, T S Browne, M S Kies, G B Gunn, A S Garden, B M Beadle, J Phan, W H Morrison, W N William, S Y Lai, R S Weber, D I Rosenthal, C D Fuller
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
L Y Li, H L Yi
Thyroid carcinoma is one of the most common cancer in the head and neck and its incidence shows an increasing tendency. Due to the special anatomical location of thyroid carcinoma, patients will have a bad prognosis outcome when cancer invades larynx and trachea. Surgical treatment is still a preferred therapy for thyroid carcinoma with laryngotracheal invasion, because it has the advantages such as high survival rate, low recurrence rate, relieving of airway obstruction, improving of postoperative quality of life...
September 7, 2016: Zhonghua Er Bi Yan Hou Tou Jing Wai Ke za Zhi, Chinese Journal of Otorhinolaryngology Head and Neck Surgery
Sharon M Lu, Shawn Iganej, Iman A Abdalla, Gary L Buchschacher
PURPOSE OF THE STUDY: In 2003, our institution adopted triweekly carboplatin (tCb) area under the curve (AUC) 5 as an alternative to high-dose cisplatin (100 mg/m) for select patients receiving definitive concurrent chemoradiation for locally advanced laryngeal carcinoma (LALC). Here, we present our experience and outcomes with this definitive concurrent chemoradiation regimen. METHODS: From January 2003 through December 2013, 53 patients with stage III (60%) or IVA (40%) LALC were treated with tCb AUC 5 and concurrent radiotherapy to 70 Gy without neoadjuvant chemotherapy...
September 15, 2016: American Journal of Clinical Oncology
William M Mendenhall, Roi Dagan, Curtis M Bryant, Robert J Amdur, Anthony A Mancuso
BACKGROUND: Depending on the extent of disease, squamous cell carcinoma (SCC) of the glottis is managed with surgery, radiotherapy (RT), or a combination of these modalities. Patients with advanced disease may receive concomitant chemotherapy in conjunction with definitive or postoperative RT. METHODS: The treatment policies of the University of Florida and patient outcomes are reviewed. RESULTS: The likelihood of cure after RT for carcinoma in situ (Tis) to T2 glottic SCC varies from 70% to 94% depending on tumor stage...
July 2016: Cancer Control: Journal of the Moffitt Cancer Center
Aron Popovtzer, Hanna Burnstein, Salomon Stemmer, Dror Limon, Ohad Hili, Gideon Bachar, Vladamir Sopov, Raphael Feinmesser, David Groshar, Jacob Shvero
BACKGROUND: The optimal treatment for locally advanced laryngeal cancer remains controversial. The purpose of this trial was to determine if the response to induction chemotherapy could select patients for organ preservation protocols, and improve larynx-preservation rates without compromising overall survival (OS). METHODS: The cohort comprised 12 patients with T3 disease and 14 with T4. Induction chemotherapy consisted of docetaxel, cisplatin, and 5-fluorouracil (TPF)...
August 24, 2016: Head & Neck
Y Pointreau, C Lafond, F Legouté, P Trémolières, S Servagi-Vernat, P Giraud, P Maingon, G Calais, M Lapeyre
Intensity-modulated radiotherapy is the gold standard in the treatment of larynx cancers (except T1 glottic tumour). Early T1 and T2 tumours may be treated by exclusive radiation or surgery. For tumours requiring total laryngectomy (T2 or T3), induction chemotherapy followed by exclusive radiotherapy or concurrent chemoradiotherapy is possible. For T4 tumour, surgery must be proposed. The treatment of lymph nodes is based on the initial treatment of the primary tumour. In non-surgical procedure, in case of sequential radiotherapy, the curative dose is 70Gy and the prophylactic dose is 50Gy...
September 2016: Cancer Radiothérapie: Journal de la Société Française de Radiothérapie Oncologique
Pierfrancesco Franco, Alba Fiorentino, Francesco Dionisi, Michele Fiore, Silvia Chiesa, Stefano Vagge, Francesco Cellini, Luciana Caravatta, Mario Tombolini, Fiorenza De Rose, Icro Meattini, Gianluca Mortellaro, Giuseppina Apicella, Lorenza Marino, Daniela Greto
PURPOSE: Combined modality therapy is a mainstay option for thoracic malignancies and head and neck cancers. The integration of different strategies is based on the multidisciplinary approach of modern clinical oncology. Radiation oncologists have to be educated, trained, and updated to provide state-of-the-art care to cancer patients and thus educational meetings are crucial. METHODS: The Italian Association of Radiation Oncology Young Members Working Group (AIRO Giovani) organized its 8th national meeting, focused on combination therapy in lung, esophageal, and head and neck cancer (with a specific focus on larynx-preservation strategies for larynx/hypopharynx tumors), involving young professionals working in Italy...
October 13, 2016: Tumori
Mitsutoshi Ooishi, Atsushi Motegi, Mitsuhiko Kawashima, Satoko Arahira, Sadamoto Zenda, Naoki Nakamura, Takaki Ariji, Sunao Tokumaru, Minoru Sakuraba, Makoto Tahara, Ryuichi Hayashi, Tetsuo Akimoto
OBJECTIVE: To evaluate the feasibility of postoperative intensity-modulated radiotherapy for head and neck cancer by investigating the patterns of failure after this therapy. METHODS: A retrospective chart review was performed. RESULTS: Between March 2006 and December 2013, 122 consecutive patients with head and neck squamous cell carcinoma were treated by surgery followed by postoperative intensity-modulated radiotherapy. In regard to the site of the primary tumor, 59 (48%) patients had cancer of the oral cavity, 31 (26%) patients had cancer of the hypopharynx, 14 (11%) patients had cancer of the oropharynx, 10 (8%) patients had cancer of the larynx and 8 (7%) patients had cancer of unknown primary...
October 2016: Japanese Journal of Clinical Oncology
Victoria Violet Wilmot, Iain James Nixon, Ioanna Fragkandrea Nixon
Juvenile laryngeal papillomatosis is the commonest cause of benign epithelial tumours of the larynx. Following diagnostic biopsy, surgical debulking is the mainstay of therapy. The condition is often recurrent with further papillomas forming after debridement, requiring serial procedures and occasionally demanding tracheostomy. Rarely, the disease can undergo malignant transformation; most commonly to squamous cell carcinoma. We describe the first reported case of small cell neuroendocrine carcinoma occurring in the previous tracheostomy site of a 29-year-old male with a history of juvenile laryngeal papillomatosis...
2016: BMJ Case Reports
B Henriques De Figueiredo, C Fortpied, J Menis, J L Lefebvre, L Barzan, D de Raucourt, L Geoffrois, L Giurgea, P Hupperets, C R Leemans, L Licitra, F Rolland, M Tesselaar, J B Vermorken, V Grégoire
The long-term results of the EORTC 24954 trial comparing sequential versus alternating chemotherapy and radiotherapy (RT) for patients with locally advanced laryngeal and hypopharyngeal cancer are reported. From 1996 to 2004, 450 patients were randomly assigned (1-1) to a sequential arm (SA = induction cisplatin-5fluorouracil followed by a 70Gy-RT for the responders or a total laryngectomy and post-operative RT for the non-responders) and an alternating arm (AA = cisplatin-5fluorouracil alternated with three 2-week courses of 20 Gy-RT for a total dose of 60 Gy)...
September 2016: European Journal of Cancer
R J De Santis, I Poon, J Lee, I Karam, D J Enepekides, K M Higgins
BACKGROUND: The literature reports various treatment methodologies, such as trans-oral laser microsurgery, radiation therapy, total/partial laryngectomies, and concurrent radiation chemotherapy for patients with early larynx cancer. However, at the forefront of early glottis treatment is trans-oral laser microsurgery and radiation therapy, likely due to better functional and survival outcomes. Here we conduct the largest Canadian head-to-head comparison of consecutive patients treated with either radiation therapy or trans-oral laser microsurgery...
2016: Journal of Otolaryngology—Head & Neck Surgery
Clifton D Fuller, Abdallah S R Mohamed, Adam S Garden, G Brandon Gunn, Collin F Mulcahy, Mark Zafereo, Jack Phan, Stephen Y Lai, Jan S Lewin, Katherine A Hutcheson, Steven J Frank, Beth M Beadle, William H Morrison, Adel K El-Naggar, Esengul Kocak-Uzel, Lawrence E Ginsberg, Merril S Kies, Randal S Weber, David I Rosenthal
BACKGROUND: The purpose of this study was to evaluate the long-term outcomes after initial definitive or adjuvant radiotherapy (RT) for T3 laryngeal cancers. METHODS: We reviewed 412 patients treated for T3 laryngeal squamous cell cancer from 1985 to 2011. RESULTS: The 10-year overall survival (OS) was 35%; disease-specific-survival (DSS) was 61%; locoregional control was 76%; and freedom from distant metastasis was 83%. Chemotherapy, age, performance status <2, node-negative status, and glottic subsite were associated with improved survival (all p < ...
July 28, 2016: Head & Neck
Sonu Goyal, Tapesh Pounikar, Preety Jain, Ramesh Arya, Jagram Verma
INTRODUCTION: Both induction chemotherapy (ICT) followed by irradiation and concurrent chemotherapy and radiotherapy have been reported as valuable alternatives to total laryngectomy in patients with advanced larynx/hypopharynx cancer. MATERIALS AND METHODS: Of the 60 enrolled patients, randomly assigned into two groups (30 in each group) previously untreated patients with stages III to IV larynx/hypopharynx squamous cell carcinoma were assigned to received two cycles of ICT with interval of 3 weeks (a) Group A paclitaxel 175 mg/m 2 on day 1 and carboplatin 450 mg on day 2 (PC), (b) Group B docetaxel and cisplatin 75 mg/m 2 each on day 1 and ifosfamide 2 g/m 2 on day 1-3 along with mesna (docetaxel-ifosfamide-cisplatin)...
April 2016: Journal of Cancer Research and Therapeutics
Whitney King, Stephen Ko, Daniel Miller
Recurrent invasive high-grade mucoepidermoid carcinoma of the larynx and hypopharynx is a rare occurrence. These tumors have been commonly associated with salivary gland tumors, most commonly the parotid gland. The patient usually presents with the following symptoms: hoarseness (if larynx is involved), or changes in voice character, sore throat, cough, odynophagia, dysphagia, otalgia, difficulty breathing, weight loss, lymphadenopathy. Here we present a case of a recurrent invasive high-grade mucoepidermoid carcinoma of larynx and hypopharynx...
June 28, 2016: Rare Tumors
Yusuke Nakata, Kei Ijichi, Nobuhiro Hanai, Daisuke Nishikawa, Hidenori Suzuki, Hitoshi Hirakawa, Takeshi Kodaira, Yasushi Fujimoto, Takashi Fujii, Takuya Miyazaki, Takeshi Shimizu, Yasuhisa Hasegawa
OBJECTIVE: To evaluate the efficacy and safety of alternating chemoradiotherapy (ACRT) with early assessment of advanced laryngeal cancer. METHODS: Patients with stage III or IV glottic or supraglottic squamous cell carcinoma were enrolled. ACRT consisted of two cycles of chemotherapy involving 5-fluorouracil and cisplatin (weeks 1 and 6) and radiotherapy (RT; weeks 2 and 7) administered alternately. An early assessment was performed after one cycle of chemotherapy and RT...
July 16, 2016: Auris, Nasus, Larynx
Saman Shahid
We observed the outcomes of chemotherapy with radiotherapy (CR) or radiotherapy (RT) alone for cancer patients of larynx, breast, blood and brain origins through complete blood count (CBC). Following were more depressed in CR patients: mean corpuscular hemoglobin-MCH & lymphocytes-LYM, hematocrit, mean corpuscular hemoglobin concentration-MCHC, hemoglobin-HB and red blood cells-RBC. In RT patients, following were more depressed: LYM, MCH and MCHC. Overall, in all cancer patients, the lymphocytes were depressed 52%...
September 2016: Critical Reviews in Oncology/hematology
Maha Al-Gilani, S Andrew Skillington, Dorina Kallogjeri, Bruce Haughey, Jay F Piccirillo
Importance: Further investigation is needed in the outcomes of currently available treatment for T3 glottic squamous cell carcinoma (SCC), a unique type of laryngeal cancer. Objective: To compare overall survival (OS) and functional outcomes among patients with T3 glottic SCC receiving nonsurgical and surgical management. Design, Setting, and Participants: This secondary analysis used data from the Surveillance, Epidemiology, and End Results (SEER) registry and Medicare databases...
October 1, 2016: JAMA Otolaryngology—Head & Neck Surgery
Adam Scheel, Emily Bellile, Jonathan B McHugh, Heather M Walline, Mark E Prince, Susan Urba, Gregory T Wolf, Avraham Eisbruch, Francis Worden, Thomas E Carey, Carol Bradford
OBJECTIVES/HYPOTHESIS: Assess tumor suppressor p53 (TP53) functional mutations in the context of other biomarkers in advanced larynx cancer. STUDY DESIGN: Prospective analysis of pretreatment tumor TP53, human papillomavirus (HPV), Bcl-xL, and cyclin D1 status in stage III and IV larynx cancer patients in a clinical trial. METHODS: TP53 exons 4 through 9 from 58 tumors were sequenced. Mutations were grouped using three classifications based on their expected function...
September 2016: Laryngoscope
Adem Binnetoglu, Tekin Baglam, Gulnur Tokuc, Kiymet Kecelioglu Binnetoglu, Fatma Gerin, Murat Sari
Background. Ewing sarcoma (ES) is a high-grade malignant tumor that has skeletal and extraskeletal forms and consists of small round cells. In the head and neck region, reported localization of extraskeletal ES includes the larynx, thyroid gland, submandibular gland, nasal fossa, pharynx, skin, and parotid gland, but not the external ear canal. Methods. We present the unique case of a 2-year-old boy with extraskeletal ES arising from the external ear canal, mimicking auricular hematoma. Results. Surgery was performed and a VAC/IE (vincristine, adriamycin, cyclophosphamide alternating with ifosfamide, and etoposide) regimen was used for adjuvant chemotherapy for 12 months...
2016: Case Reports in Otolaryngology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"